Cardiac remodeling hypertensive patients with different forms of thyroid dysfunction

Objective. To analyze the changes in the structural and functional characteristics of the heart, clinical severity of heart failure (HF) and the levels of N-terminal fragment of the brain natriuretic peptide (NT-proBNP) in patients with arterial hypertension (HTN) and various forms of the thyroid dysfunction (TD). Design and methods. The total of 101 HTN patients were included in the study: 40 with hypothyroidism; 39 — with hyperthyroidism, 22 — without any TD. Control group consisted of 20 persons without any cardiovascular pathology and TD. Basic structural and functional parameters of the heart, serum levels of NT-proBNP were studied. Results. In patients with TD, HF was revealed significantly more often than in the group of AH without TD. There with patients with hypothyroidism had higher, HF functional class compared to the group of hyperthyroidism. In the group of HTN with hypothyroidism left ventricular (LV) hypertrophy and decrease of E/A ratio were observed, whereas patients with HTN and hyperthyroidism were characterized by LV dilatation and by a significant increase of serum NTproBNP level. Conclusions. In HTN patients with hyperthyroidism cardiac remodeling is characterized by the prevalence of LV dilatation, whereas in hypothyroidism LV hypertrophy with LV diastolic dysfunction dominate. Hyperthyroidism is also associated with increased NT-proBNP serum levels.

arterial hypertension, hypothyroidism, hyperthyroidism, cardiovascular system, heart remodeling, brain natriuretic peptide, heart failure

1. Klein I, Ojamaa K. Thyroid hormone and the cardiovascular system. N Engl J Med. 2001;344(7):501–509. doi:10.1056/ NEJM200102153440707

2. Osuna PM, Udovcic M. Hyperthyroidism and the Heart. Methodist Debakey Cardiovasc J. 2017;13(2):704–730. doi:10.14797/ mdcj-13-2-60

3. Klein I, Danzi S. Thyroid disease and the heart. Curr Probl Cardiol. 2016;41(2):65–92. doi:10.1016/j.cpcardiol.2015.04.002

4. Вербовой А. Ф., Капралова И. Ю., Шаронова Л. А. Содержание адипокинов и показатели эхокардиографии у женщин с гипотиреозом. Клиницист. 2014;8(2):19–21. doi:10.17650/1818-8338- 2014-2-17-21 [Verbovo AF, Kapralova IU, SHaronova LA. The content of adipokines and echocardiography in women with hypothyroidism. Klinitsist. = The Physician. 2014;8(2):19–2. doi:10.17650/1818-8338- 2014-2-17-21 In Russian].

5. Grais IM, Sowers JR. Thyroid and the Heart. Am J Med. 2014;127(8):691–698. doi:10.1016/j.amjmed.2014.03.009

6. Udovcic M, Pena RH, Patham B, Tabatabai L, Kansara A. Hypothyroidism and the Heart. Methodist Debakey Cardiovasc J. 2017;13(2):55–59. doi:10.14797/mdcj-13-2-55

7. Mourouzis I, Forini F, Pantos C, Iervasi G. Thyroid hormone and cardiac disease: from basic concepts to clinical application. J Thyroid Res. 2011;2011:958626. doi:10.4061/2011/958626

8. Iervasi G, Pingitore A, Landi P, Raciti M, Ripoli A, Scarlattini M et al. Low-T3 syndrome a strong prognostic predictor of death in patients with heart disease. Circulation. 2003;107(5):708–713. doi:10.1161/01.CIR.0000048124.64204.3F

9. Pingitore A, Landi P, Taddei MC, Ripoli A, L’Abbate A, Iervasi G. Triiodothyronine levels for risk stratification of patients with chronic heart failure. Am J Med. 2005;118(2):132–136. doi:10.1016/j.amjmed.2004.07.052

10. Wassen F, Schiel A, Kuiper G, Kaptein E, Bakker O, Visser TJ et al. Induction ofthyroid hormone-degrading deiodinase in cardiac hypertrophyand failure. Endocrinology. 2005;143(7): 2812–2815. doi:10.1210/en.143.7.2812

11. Rodondi N, Newman AB, Vittinghoff E, de Rekeneire N, Satterfield S, Harris TB et al. Subclinical hypothyroidism and the risk of heart failure, other cardiovascular events, and death. Arch Intern Med. 2005;165(21):2460–2466. doi:10.1001/archinte. 165.21.2460

12. Ozmen B, Ozmen D, Parildar Z, Mutaf I, Bayindir O. Serum N-terminal-pro-B type Natriuretic Peptide (NT-pro-BNP) levels in hyperthyroidism and hypothyroidism. Endocr Res. 2007;32 (1–2):1–8. PMID:18271501

13. Ertugrul DT, Gursoy A, Sahin M, Unal AD, Pamuk B, Berberoglu Z et al. Evaluation brain natriuretic peptide levels in hyperthyroidism and hypothyroidism. J Nat Med Assoc. 2008;100 (4):401–405. doi:10.1016/S0027-9684(15)31272-4

14. Диагностика и лечение артериальной гипертензии. Российские рекомендации (четвертый пересмотр). Системные гипертензии. 2010;3:5–26. [Diagnosis and treatment of hypertension. Russian recommendations (fourth revision). Sistemnye Gipertenzii = Systemic Hypertension. 2010;3:5–26. In Russian].

15. Клинические рекомендации по диагностике и лечению тиреотоксикоза с диффузным зобом (диффузный токсический зоб, болезнь Грейвса–Базедова), узловым/многоузловым зобом. Общественная организация «Российская ассоциация эндокринологов». Москва. 2014;25. [Clinical recommendations for diagnosis and treatment of thyrotoxicosis with diffuse goiter (diffuse toxic goiter, Graves-Bazedov's disease), nodal/multinodular goiter Public organization “Russian Endocrinology Association”. Moscow. 2014;25. In Russian].

16. Jonklaas J, Bianco AC, Bauer AJ, Burman KD, Cappola AR, Celi FS et al. Guidelines for the treatment of hypothyroidism: prepared by the american thyroid association task force on thyroid hormone replacement. Thyroid. 2014;24(12):1670–1751. doi:10.1089/ thy.2014;0028

17. Kato K, Murakami H, Isozaki O, Tsushima T, Takano K. Serum concentrations of BNP and ANP in patients with thyrotoxicosis. Endocr J. 2009;56(1):17–27. doi:10.1507/endocrj.k08e-145

18. Ripoli A, Pingitore A, Favilli B, Bottoni A, Turchi S, Osman NF et al. Does subclinical hypothyroidism affect cardiac pump performance? Evidence from a magnetic resonance imaging study. J Am Coll Cardiol. 2005;45(3):439–445. doi:10.1016/j. jacc.2004.10.044

19. Brenta G, Mutti LA, Schnitman M, Fretes O, Perrone A, Matute ML. Assessment of left ventricular diastolic function by radionuclide ventriculography at rest and exercise in subclinical hypothyroidism, and its response to l-thyroxine therapy. Am J Cardiol. 2003;91(11):1327–1330. PMID:12767425.

20. Hanft LM, Korte FS, McDonald KS. Cardiac function and modulation of sarcomeric function by length. Cardiovasc Res. 2008;77(4):627–636. doi:10.1093/cvr/cvm099

21. Kranias EG, Hajjar RJ. Modulation of cardiac contractility by the phospholamban/SERCA2a regulatome. Circ Res. 2013;110 (12):1646–1660. doi:10.1161/CIRCRESAHA.111.259754